Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stangel

Showing results (21-30 of 70) with videos related to

Pageof 7
Sort By:
Journal of Neuroimmunology|May 25, 1999
Polyclonal immunoglobulins for intravenous use do not influence the behaviour of cultured oligodendrocytesM Stangel, A Compston, N J Scolding
Clinical Neuroradiology|July 23, 2015
MRI in the Diagnosis and Monitoring of Multiple Sclerosis: An UpdateM P Wattjes, M D Steenwijk, M Stangel
Clinical and Experimental Immunology|December 30, 2014
7(th) International Immunoglobulin Conference: Poster presentationsK Warnatz, M Ballow, M Stangel, et al.
Clinical and Experimental Immunology|December 30, 2014
7th International Immunoglobulin Conference: Poster presentationsK Warnatz, M Ballow, M Stangel, et al.
Journal of the Neurological Sciences|March 25, 1998
Intravenous immunoglobulin treatment of neurological autoimmune diseasesM Stangel, H P Hartung, P Marx, et al.
Der Nervenarzt|July 1, 2015
[New therapeutic strategies for remyelination in multiple sclerosis]D Kremer, H-P Hartung, M Stangel, et al.
Clinical Neuropharmacology|October 23, 1997
Side effects of high-dose intravenous immunoglobulinsM Stangel, H P Hartung, P Marx, et al.
Microscopy Research and Technique|December 19, 2001
Oxides and apoptosis in inflammatory myopathiesM Stangel, E Mix, U K Zettl, et al.
Der Nervenarzt|October 11, 2003
[Chemokine--possible new options for the treatment of multiple sclerosis]C Trebst, R M Ransohoff, A Windhagen, et al.
Biochemical and Biophysical Research Communications|August 15, 1994
Bacterial expression of a soluble T-cell receptor alpha chainM Stangel, K V Toyka, H P Hartung, et al.
Pageof 7

Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
Journal of Neuroimmunology|May 25, 1999
Polyclonal immunoglobulins for intravenous use do not influence the behaviour of cultured oligodendrocytesM Stangel, A Compston, N J Scolding
Clinical Neuroradiology|July 23, 2015
MRI in the Diagnosis and Monitoring of Multiple Sclerosis: An UpdateM P Wattjes, M D Steenwijk, M Stangel
Clinical and Experimental Immunology|December 30, 2014
7(th) International Immunoglobulin Conference: Poster presentationsK Warnatz, M Ballow, M Stangel, et al.
Clinical and Experimental Immunology|December 30, 2014
7th International Immunoglobulin Conference: Poster presentationsK Warnatz, M Ballow, M Stangel, et al.
Journal of the Neurological Sciences|March 25, 1998
Intravenous immunoglobulin treatment of neurological autoimmune diseasesM Stangel, H P Hartung, P Marx, et al.
Der Nervenarzt|July 1, 2015
[New therapeutic strategies for remyelination in multiple sclerosis]D Kremer, H-P Hartung, M Stangel, et al.
Clinical Neuropharmacology|October 23, 1997
Side effects of high-dose intravenous immunoglobulinsM Stangel, H P Hartung, P Marx, et al.
Microscopy Research and Technique|December 19, 2001
Oxides and apoptosis in inflammatory myopathiesM Stangel, E Mix, U K Zettl, et al.
Der Nervenarzt|October 11, 2003
[Chemokine--possible new options for the treatment of multiple sclerosis]C Trebst, R M Ransohoff, A Windhagen, et al.
Biochemical and Biophysical Research Communications|August 15, 1994
Bacterial expression of a soluble T-cell receptor alpha chainM Stangel, K V Toyka, H P Hartung, et al.
Pageof 7